- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Schering and Alliance complete deal
Schering and Alliance Pharmaceutical finalized their agreement last month regarding Imagent US, Alliance's ultrasound contrast agent, and provided additional details about the deal. The two companies will jointly develop the product, which will be
Schering and Alliance Pharmaceutical finalized their agreement last month regarding Imagent US, Alliance's ultrasound contrast agent, and provided additional details about the deal. The two companies will jointly develop the product, which will be marketed exclusively by Schering, of Berlin, Germany.
In exchange for the license, Schering will pay San Diego-based Alliance a $4 million licensing fee, plus additional payments predicated on the achievement of specified milestones and royalty payments based on worldwide sales. The payments could amount to $65 million if clinical trials, regulatory approvals, and market introductions result in a minimum amount of revenues. In addition, Schering's Schering Berlin Venture purchased $10 million in Alliance convertible preferred stock.
FDA Clears AI-Powered Quantitative Perfusion Mapping for Cone-Beam CT
May 6th 2024Reportedly validated in more than 10 clinical trials, the AngioFlow perfusion imaging software enables timely identification of brain regions with cerebral blood flow reduction and those with significant hypoperfusion.
